Cenobamate: real-world data from a retrospective multicenter study
Open Access
- 1 July 2024
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (10) , 6596-6604
Abstract
Background: Clinical trials have shown that cenobamate (CNB) is an efficacious and safe anti-seizure medication (ASM) for drug-resistant focal epilepsy. Here, we analyzed one of the largest real-world cohorts, covering the entire spectrum of epilepsy syndromes, the efficacy and safety of CNB, and resulting changes in concomitant ASMs. Methods: We conducted a retrospective observational study investigating CNB usage in two German tertiary referral centers between October 2020 and June 2023 with follow-up data up to 27 months of treatment. Our primary outcome was treatment response. Secondary outcomes comprised drug response after 12 and 18 months, seizure freedom rates, CNB dosage and retention, adverse drug reactions (ADRs), and changes in concomitant ASMs. Results: 116 patients received CNB for at least two weeks. At 6 months, 98 patients were eligible for evaluation. Thereof 50% (49/98) were responders with no relevant change at 12 and 18 months. Seizure freedom was achieved in 18.4% (18/98) at 6 months, 16.7% (11/66), and 3.0% (1/33) at 12 and 18 months. The number of previous ASMs did not affect the seizure response rate. Overall, CNB was well-tolerated, however, in 7.7% (9/116), ADRs led to treatment discontinuation. The most frequent changes of concomitant ASMs included the discontinuation or reduction of sodium channel inhibitors, clobazam reduction, and perampanel discontinuation, while brivaracetam doses were usually left unchanged. Conclusions: CNB proved to be a highly effective and generally well-tolerated ASM in patients with severe drug-resistant epilepsy, comprising a broad array of epilepsy syndromes beyond focal epilepsy.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (FOR-2715, Le1030/15-1)
- Bundesministerium für Forschung, Technologie und Raumfahrt (BMBF, 01GM2210B)
- Universitätsklinikum Tübingen
This publication has 25 references indexed in Scilit:
- Real-world experience with cenobamate: A systematic review and meta-analysisSeizure: European Journal of Epilepsy, 2023
- Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient RecordsCNS Drugs, 2023
- Cenobamate in patients with highly refractory focal epilepsy: A retrospective real-world studySeizure: European Journal of Epilepsy, 2023
- Real‐world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access ProgramEpilepsia Open, 2023
- Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus RecommendationsNeurology and Therapy, 2022
- Efficacy and safety of adjunctive cenobamate: Post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medicationsSeizure: European Journal of Epilepsy, 2022
- Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trialThe Lancet Neurology, 2020
- Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neuronsEuropean Journal of Pharmacology, 2019
- The current place of epilepsy surgeryCurrent Opinion in Neurology, 2018
- Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic DrugsJAMA Neurology, 2018